|Targets||Toll-like Receptor (TLR)|
|Description||This active molecular is a selective TLR7 (Toll-like receptor 7) agonist with preferential Type-1 IFN-stimulating properties which is under development of GlaxoSmithKline. GSK2245035 displays potent IFNα inducing potency and IFNα/TNFα selectivity. In Aug 2015, GlaxoSmithKline completed a phase II follow-up trial for Allergic asthma and Allergic rhinitis in Canada. In Jul 2016, GlaxoSmithKline planed a phase II trial for Allergic asthma in Germany (Intranasal).|
|Synonyms||(S)-6-amino-2-(pentan-2-yloxy)-9-(5-(piperidin-1-yl)pentyl)-7,9-dihydro-8H-purin-8-one;1325212-97-2 (maleate salt)|
|Solubility||Soluble in DMSO|
|Application||Allergic asthma; Allergic rhinitis|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator GlaxoSmithKline|
CU CPT 4a
Selective TLR3 inhibitor(IC50 = 3.44 μM in RAW 264.7 cells)
C29 was identified as a potential TLR2 inhibitor.
An agonist of TLR7
A novel synthetic antagonist for nucleic acid-sensing TLRs
A potent TLR7 agonist (EC50 = 7.2 nM)
CPG52364 sulfate is the sulfate form of CPG52364, which is a small molecule toll-like receptor(TLR) antagonist. It has recently completed phase 1 clinical trial...
Polyadenylic acid-Polyuridylic acid sodi
A thiazoloquinolone derivative that stimulates TLR8 in human peripheral blood mononuclear cells
Human TLR7/8 and mouse TLR7 agonist
Pam2CSK4 Biotin is the biotinylated Pam2CSK4. Pam2CSK4, a synthetic diacylated lipopeptide (LP), is a toll-like receptor 2/6 (TLR2/6) agonist, and induces TNF-α...
Agonist of TLR9; An immunomodulating synthetic oligonucleotide; As a monotherapy and in combination with chemotherapeutic agents, and also as an adjuvant for va...
TLR3 agonist; Made of one strand each of polyinosinic acid and polycytidylic acid
This active molecular is a selective TLR7 (Toll-like receptor 7) agonist with preferential Type-1 IFN-stimulating properties which is under development of Glaxo...
A small-molecule agonist of TLR7
A potent small-molecule agonist of TLR1/2(EC50 = 52.9 nM)
TLR9 inhibitor; Autophagy inhibitor
TLR2 agonist; A synthetic diacylated lipopeptide
An agonist of TLR7 with immune response modifying activity; Approved for basal cell carcinoma; In Phase III for VIN and CIN; Imiquimod's proapoptotic activity ...
An imidazoquinolinamine and TLR7 agonist with antitumor and antiviral activity; Phase I
A potent and oral agonist of TLR7